Frequently Asked Questions


It can be both, for a pilot it could be a new tissue or a new tissue and new antibodies. If at any point we have to optimize an antibody, then it becomes antibody feasibility.

We perform a concentration and titration assessment that evaluates the optimal concentration level of any given tissue preferably done with control tissues.

ClearLight Biotechnologies’ technology could be easily applied to most biological areas that rely on 2D thin-section analysis of a tissue. Bring us your burning question even if it is outside the area of oncology or neuroscience.

No. ClearLight Biotechnologies provides study-related services to sponsors of drug research programs early in the drug development cycle. Our contract research and development services are for Research Use Only (RUO).

We currently perform non-destructive tissue processing and future digital spatial image analysis in 3D to facilitate pre-clinical and clinical research studies. CLARITY combined with CRYSTAL will enable ClearLight to fully automate the process, to achieve competitive turnaround times associated with 2D thin section IHC methods.

See Sample Requirements on the Services page. We may support situations not shown. Start a conversation with us using the Contact Us form, email, call (800) 251-8905 or chat with us online.

ClearLight is currently developing an automated platform that is based on the CLARITY technology and will be initially offered as an internal service and then eventually as a RUO instrument in the field.  No, we don’t currently offer reagents; however, we do offer collaborative tissue clearing services using the CLARITY method while we are developing our automated capabilities. See Services to learn about our current offering.


ClearLight’s technology is being developed to eventually evaluate true 3D relationships within a volume of diseased and normal tissue. By examining the tissue in a 3D volume, the CLARITY platform will allow a better understanding of the molecular heterogeneity within that tumor sample. The up and coming, Tru3D™ analysis software will be able to process image files of multiplex IHC stained tissues and analyzes the tissue sample in 3D. The current proprietary 3D Software workflow is Raw Data –> Cell Segmentation –> Classification –> Analysis. Samples in our published papers were imaged on a Leica SP8 confocal microscope and using Bitplane Imaris 9.2.1 software as this was prior to the development of our proprietary software. Learn More.

Active or passive CLARITY tissue clearing is a very powerful and useful method, but lipid clearing and staining times take longer time than optimal for use in future clinical and diagnostic settings. CRYSTAL technology is a significant improvement to both the active and passive CLARITY tissue clearing methods by aiming detergent streams at specific areas of the tissue sample to be cleared. This can speed up the clearing process significantly, increasing the diagnostic relevance and usefulness of this technology in a clinical setting.

ClearLight Biotechnologies has signed an exclusive worldwide licensing agreement to develop and commercialize CRYSTAL, a three-dimensional (3-D) tissue-clearing technology. Learn more about CRYSTAL on the resources page.

Staining can be performed on the tissue sample without interference from the hydrogel matrix. With CLARITY tissue clearing, the sample is processed via Multiplex IHC staining, allowing the characteristics of the tumor microenvironment to be fully analyzed in three dimensions.

The tissue sample is with a hydrogel matrix solution, allowing covalent cross-linking of biological molecules to the hydrogel resulting in a matrix that remains intact even as light scattering lipids are cleared away.

The CLARITY method utilizes specific detergents, to remove the lipids, or fatty tissues, from a tissue sample.

CLARITY was first made public in a paper published in Nature in 2013.
[ K Chung, J Wallace, S-Y Kim, S Kalyanasundaram, AS Andalman, TJ Davidson, JJ Mirzabekov, KA Zalocusky, J Mattis, AK Denisin, S Pak, H Bernstein, C Ramakrishnan, L Grosenick, V Gradinaru, and K Deisseroth. Structural and molecular interrogation of intact biological systems. Nature (2013) 497: 332-337.]

No, the CLARITY method was originally developed at the Karl Deisseroth Lab at Stanford University Medical Center. Dr. Deisseroth is a founder and scientific advisor to ClearLight Biotechnologies.  However, ClearLight is automating the method so that it can be utilized by researchers and eventually clinicians across the world.

CLARITY is an acronym for Clear Lipid-exchanged Acrylamide-hybridized Rigid Imaging / Immunostaining / in situ-hybridization-compatible Tissue hYdrogel. Learn more about our technology.

Load More

Analysis can be performed for select biomarkers, please contact us to find out if your target of interest is one of them. Imaging is currently performed on select fields of view instead of the entire sample.

Submission Guidelines

Tissue Sample Requirements: